Herein we have reviewed our recent developments for the identification of new tacrine
analogues for Alzheimer's disease (AD) therapy. Tacrine, the first cholinesterase inhibitor …

Tacrine was the first drug approved for the treatment of Alzheimer's disease (AD) in 1993,
which was withdrawn in 2013 due to its hepatotoxicity. However, new, non-hepatotoxic …

Although the mechanism of Alzheimer's disease (AD) is still not fully understood, the
development of multifunctional AChE inhibitors remains a research focus for AD treatment …

Alzheimer's disease (AD) is a well‐known neurodegenerative disorder affecting millions of
old people worldwide and the corresponding epidemiological data emphasize the …

Aim To prepare polymer-drug conjugates containing a combination of memantine, tacrine,
and E)-N-(3-aminopropyl) cinnamide, promising therapeutics for the treatment of …

Alzheimer's disease (AD) is one of the most common age-related neurodegenerative
disorders. Aggregation of amyloid-β peptide into extracellular plaques with incorporation of …

Notwithstanding the clinical use of tacrine was hampered by severe hepatotoxicity, tacrine
still remains a reference scaffold in the search for new efficient drugs for Alzheimer's disease …

Alzheimer's disease (AD) is the most common form of dementia. It'sa chronic and
untreatable neurodegenerative disease with irreversible progression and has important …

Tacrine, the first drug approved for the treatment of Alzheimer's disease (AD), is a non-
competitive cholinesterase inhibitor withdrawn due to its acute hepatotoxicity. However, new …

Alzheimer's disease (AD) is a complex, neurodegenerative pathology showing, among
others, high cholinergic and neurotransmitter deficits, oxidative stress, inflammation, Aβ …